IP Library Granted Patent US 9,700,023
Granted Patent B2
US 9,700,023 · App. 14/132,969 · Granted Jul 11, 2017

Rat embryonic stem cell

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,700,023
App. No.
14/132,969
Granted
Jul 11, 2017
Kind
B2
Abstract

The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.

Claims (45)

1. A method of producing a chimeric rat, which comprises performing a process comprising the following steps (X)-(Z):

(X) a step for introducing a desired gene into a rat embryonic stem cell,

(Y) a step for preparing a chimeric rat embryo for transplantation by (i) injecting the rat embryonic stem cell into which the gene was introduced into a blastocoele of a rat blastocyst or a morula stage- or 16-cell stage-rat embryo or (ii) co-culturing the rat embryonic stem cell into which the gene was introduced with two 8-cell stage-rat embryos without zona pellucidas,

(Z) a step for transferring the chimeric rat embryo for transplantation into the uterus of a pseudopregnant female rat to produce the chimeric rat, wherein the rat embryonic stem cell has the following properties (a)-(k):

(a) expressing Oct3/4 gene and Nanog gene,

(b) positive for alkaline phosphatase activity,

(c) having an embryoid body forming ability,

(d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4,

(e) having the same number of chromosomes as does a normal rat cell,

(f) capable of being subcultured and holding the undifferentiated state,

(g) having in vitro pluripotency,

(h) having a potential to differentiate for cells of three embryonic germ lineages,

(i) having teratoma formation ability,

(j) having an ability to produce a chimeric rat,

(k) being germline-competent,

wherein the rat embryonic stem cell is obtained by the method consisting essentially of the following steps (A)-(E) performed using a culture medium with 2% or less serum concentration:

(A) culturing a rat blastocyst on inactivated mouse embryonic fibroblasts in a leukemia inhibitory factor (LIF)-free culture medium to form an inner cell mass in the blastocyst,

(B) dissociating the inner cell mass, wherein the dissociated inner cell mass is in a cell aggregate state,

(C) culturing primary embryonic stem cells resulting from a culture of the dissociated inner cell mass on inactivated mouse embryonic fibroblasts until the primary embryonic stem cells can be passaged,

(D) dissociating the primary embryonic stem cells, which can be passaged, wherein the dissociated primary embryonic stem cells are in a cell aggregate state,

(E) culturing the dissociated primary embryonic stem cells on inactivated mouse embryonic fibroblasts to establish an embryonic stem cell,

wherein a rat leukemia inhibitory factor (rLIF)-containing culture medium is used in steps (C)-(E).

2. A method of producing a genetically modified rat, which comprises a step for crossing a chimeric rat with a wild-type rat to produce a heterozygous genetically modified rat, wherein the chimeric rat is produced by a process comprising the following steps (X)-(Z):

(X) a step for introducing a desired gene into a rat embryonic stem cell,

(Y) a step for preparing a chimeric rat embryo for transplantation by (i) injecting the rat embryonic stem cell into which the gene was introduced into a blastocoele of a rat blastocyst or a morula stage- or 16-cell stage-rat embryo or (ii) co-culturing the rat embryonic stem cell into which the gene was introduced with two 8-cell stage-rat embryos without zona pellucidas,

(Z) a step for transferring the chimeric rat embryo for transplantation into the uterus of a pseudopregnant female rat to produce the chimeric rat, wherein the rat embryonic stem cell has the following properties (a)-(k):

(a) expressing Oct3/4 gene and Nanog gene,

(b) positive for alkaline phosphatase activity,

(c) having an embryoid body forming ability,

(d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4,

(e) having the same number of chromosomes as does a normal rat cell,

(f) capable of being subcultured and holding the undifferentiated state,

(g) having in vitro pluripotency,

(h) having a potential to differentiate for cells of three embryonic germ lineages,

(i) having teratoma formation ability,

(j) having an ability to produce a chimeric rat,

(k) being germline-competent,

wherein the rat embryonic stem cell is obtained by the method consisting essentially of the following steps (A)-(E) performed using a culture medium with 2% or less serum concentration:

(A) culturing a rat blastocyst on inactivated mouse embryonic fibroblasts in a leukemia inhibitory factor (LIF)-free culture medium to form an inner cell mass in the blastocyst,

(B) dissociating the inner cell mass, wherein the dissociated inner cell mass is in a cell aggregate state,

(C) culturing primary embryonic stem cells resulting from a culture of the dissociated inner cell mass on inactivated mouse embryonic fibroblasts until the primary embryonic stem cells can be passaged,

(D) dissociating the primary embryonic stem cells, which can be passaged, wherein the dissociated primary embryonic stem cells are in a cell aggregate state,

(E) culturing the dissociated primary embryonic stem cells on inactivated mouse embryonic fibroblasts to establish an embryonic stem cell, wherein a rat leukemia inhibitory factor (rLIF)-containing culture medium is used in steps (C)-(E).

3. The method of claim 2 , wherein the genetically modified rat is a knockout rat or a knockin rat, and wherein (X) the step for introducing a desired gene into a rat embryonic stem cell comprises introducing a targeting vector into a target gene in the genome of the rat embryonic stem cell by homologous recombination to produce a homologously recombined rat embryonic stem cell.

4. The method of claim 2 , wherein the genetically modified rat is a knockdown rat, and wherein (X) the step for introducing a desired gene into a rat embryonic stem cell comprises introducing a vector comprising siRNA or an antisense nucleic acid into the rat embryonic stem cell and expressing the siRNA or antisense nucleic acid to suppress expression of a target gene.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: DS PHARMA BIOMEDICAL CO., LTD.
To: SUMITOMO CHEMICAL COMPANY, LIMITED
Reel/Frame 048724/0360 →
ADDRESS CHANGE Recorded Nov 28, 2017
From: DS PHARMA BIOMEDICAL CO., LTD.
To: DS PHARMA BIOMEDICAL CO., LTD.
Reel/Frame 044514/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2016
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: DS PHARMA BIOMEDICAL CO., LTD.
Reel/Frame 039759/0163 →
CHANGE OF NAME Recorded Aug 25, 2014
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 033606/0307 →